MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.96
+0.20
+2.28%
After Hours: 8.95 -0.01 -0.11% 17:51 07/14 EDT
OPEN
8.78
PREV CLOSE
8.76
HIGH
8.98
LOW
8.75
VOLUME
3.32M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.02
MARKET CAP
1.87B
P/E (TTM)
-34.6883
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCRX last week (0707-0711)?
Weekly Report · 22h ago
BioCryst Pharmaceuticals Files Initial Statement of Beneficial Ownership for CFO & Head of Corp Development, Ghias Babar
Reuters · 3d ago
BioCryst Pharmaceuticals’ BCX9930 Study Termination: Implications for Investors
TipRanks · 4d ago
BRIEF-Island Pharmaceuticals Announces Purchase Of Galidesivir Antiviral Program From Biocryst Pharmaceuticals
Reuters · 6d ago
BioCryst appoints Babar Ghias as CFO
Seeking Alpha · 07/07 11:38
BioCryst Appoints New CFO to Drive Growth
TipRanks · 07/07 11:28
BioCryst appoints Babar Ghias as CFO, head of corporate development
TipRanks · 07/07 11:25
BioCryst Pharmaceuticals Names Babar Ghias Chief Financial Officer
Dow Jones · 07/07 11:24
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.